Cargando…
Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy
BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632495/ https://www.ncbi.nlm.nih.gov/pubmed/23566361 http://dx.doi.org/10.1186/1746-1596-8-57 |
_version_ | 1782266866641666048 |
---|---|
author | Kobayashi, Kazuhiro Saito, Toshihiro Kitamura, Yasuo Nobushita, Tomohiro Kawasaki, Takashi Hara, Noboru Takahashi, Kota |
author_facet | Kobayashi, Kazuhiro Saito, Toshihiro Kitamura, Yasuo Nobushita, Tomohiro Kawasaki, Takashi Hara, Noboru Takahashi, Kota |
author_sort | Kobayashi, Kazuhiro |
collection | PubMed |
description | BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological outcomes in those managed with surveillance. METHODS: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance. RESULTS: No patient had cause-specific death during the mean observation period of 104 and 99 months in men with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and 4 (6.6%) men managed with surveillance had disease relapse; the 10-year relapse-free survival (RFS) rate was 93.4% in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without (10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had a poorer RFS than those without; 40.0% and 18.7% of the patients with and without lymphovascular invasion had disease relapse, respectively, although the difference was not significant (logrank P=0.17). CONCLUSION: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion may possibly be at high risk for disease relapse. |
format | Online Article Text |
id | pubmed-3632495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36324952013-04-23 Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy Kobayashi, Kazuhiro Saito, Toshihiro Kitamura, Yasuo Nobushita, Tomohiro Kawasaki, Takashi Hara, Noboru Takahashi, Kota Diagn Pathol Research BACKGROUND: Surveillance after orchiectomy has recently been a management option in patients with stage I seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological outcomes in those managed with surveillance. METHODS: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance. RESULTS: No patient had cause-specific death during the mean observation period of 104 and 99 months in men with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and 4 (6.6%) men managed with surveillance had disease relapse; the 10-year relapse-free survival (RFS) rate was 93.4% in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without (10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had a poorer RFS than those without; 40.0% and 18.7% of the patients with and without lymphovascular invasion had disease relapse, respectively, although the difference was not significant (logrank P=0.17). CONCLUSION: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion may possibly be at high risk for disease relapse. BioMed Central 2013-04-08 /pmc/articles/PMC3632495/ /pubmed/23566361 http://dx.doi.org/10.1186/1746-1596-8-57 Text en Copyright © 2013 Kobayashi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kobayashi, Kazuhiro Saito, Toshihiro Kitamura, Yasuo Nobushita, Tomohiro Kawasaki, Takashi Hara, Noboru Takahashi, Kota Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title | Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title_full | Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title_fullStr | Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title_full_unstemmed | Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title_short | Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
title_sort | oncological outcomes in patients with stage i testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632495/ https://www.ncbi.nlm.nih.gov/pubmed/23566361 http://dx.doi.org/10.1186/1746-1596-8-57 |
work_keys_str_mv | AT kobayashikazuhiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT saitotoshihiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT kitamurayasuo oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT nobushitatomohiro oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT kawasakitakashi oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT haranoboru oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy AT takahashikota oncologicaloutcomesinpatientswithstageitesticularseminomaandnonseminomapathologicalriskfactorsforrelapseandfeasibilityofsurveillanceafterorchiectomy |